Dr. Hutson on the future of the advanced renal cell carcinoma treatment paradigm
“The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies,” says Thomas E. Hutson, DO, PharmD, FACP.
In this video, Thomas E. Hutson, DO, PharmD, FACP, shares his vision for the future of patient treatment in the field of advance renal cell carcinoma (RCC).Hutson is the director of the urologic oncology program at Baylor University Medical Center in Dallas, Texas.
Transcript
The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies. And I hope that we move forward with different biomarkers that will help us separate certain patient groups out so that they can receive the best, and I'll put in quotation marks “targeted therapies,” to give them the best outcome with the least side effects. So, we're recognizing that that one person's kidney cancer is not the same as the other’s. And it's time now that we can apply all the advances across the cancer spectrum in general to kidney cancer.
Transcript has been edited for clarity.
TAR-200 sustains impressive clinical activity in BCG-unresponsive NMIBC
May 3rd 2024Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to the latest results from the phase 2b SUNRISE-1 trial.
